Brevilin A
Brevilin A is an orally active STAT3/JAK inhibitor (STAT3 IC50= 10.6 μM) . Brevilin A shows anti-tumor activity, anti-proliferative activity to cancer cells, and can induce apoptosis and autophagy[1][2].
Product Specifications
CAS Number
16503-32-5
UNSPSC
12352005
Hazard Statement
H317
Target
Apoptosis; Autophagy; JAK; STAT
Type
Natural Products
Related Pathways
Apoptosis; Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/brevilin-a.html
Purity
99.86
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
C/C=C(C)\C(O[C@H]1[C@@]([C@@H]2C)([H])[C@@](OC2=O)([H])C[C@@H](C)[C@@]3([H])[C@]1(C(C=C3)=O)C)=O
Molecular Formula
C20H26O5
Molecular Weight
346.42
Precautions
H317
References & Citations
[1]Chen X, et al. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells. PLoS One. 2013 May 21;8 (5) :e63697.|[2]You P, et al. Brevilin A induces apoptosis and autophagy of colon adenocarcinoma cell CT26 via mitochondrial pathway and PI3K/AKT/mTOR inactivation. Biomed Pharmacother. 2018 Feb;98:619-625.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Natural Products
Clinical Information
No Development Reported
Isoform
STAT3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
51362111 3x 1.0 µg
ZNF221 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)
Sign In for Pricing
View Details 